BMRN
BioMarin Pharmaceutical Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-11/100
Last price
55.91
▼ 1.63 (2.83%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
57.50
Prev close
57.54
Day high
57.88
Day low
55.76
Volume
3.72M
Market cap
$10.88B
P/E (TTM)
151.95
52W range
49.26 – 70.98
Day trading desk
Gap from prior close
-0.07%
Prior close 57.54
VWAP
56.28
-0.66% from price
Relative volume
2.63×
Unusually busy
Session range
4.28%
55.50 – 57.88
Position in range
17%
Near session low
ATR (14D)
1.53
2.74% of price
Prior day high
58.11
PDH
Prior day low
56.82
PDL
Bid / ask spread
—
Quote not published
Session volume
5.27M
Avg 2.00M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.10%
-8.0%
1M
-15.50%
-16.7%
3M
-5.91%
-10.4%
6M
0.00%
-18.2%
YTD
-5.40%
-19.7%
1Y
+1.43%
-15.0%
3Y
-36.46%
-118.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BMRN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+52.71K
Net buying
Buy transactions
10
73.55K shares
Sell transactions
2
20.84K shares
Net transactions
+12
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
658.15K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 10, 26 | PLENGE ROBERT M Director |
STOCK | 6.14K | $0 | Direct |
| Sep 2, 26 | DAVIS GEORGE ERIC Officer |
SELL | 17.56K | $1.16M | Direct |
| Jun 2, 26 | COUNTOURIOTIS ATHENA M Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | ENYEDY MARK J Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | HO MAYKIN Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | BODEM BARBARA W Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | ANDERSON ELIZABETH M Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | HOMBACH ROBERT J. CPA Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | DERE WILLARD H Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | CLARK IAN THORNTON Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | WALBERT TIMOTHY P Director |
STOCK | 7.49K | $0 | Direct |
| May 7, 26 | FRIBERG GREGORY R Officer |
SELL | 3.28K | $176.68K | Direct |
| Mar 16, 26 | DAVIS GEORGE ERIC Officer |
STOCK | 14.57K | $0 | Direct |
| Mar 16, 26 | MUELLER BRIAN R Chief Financial Officer |
STOCK | 18.74K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDERSON ELIZABETH M |
Director | 41.94K | Stock Award(Grant) |
DAVIS GEORGE ERIC |
Officer | 61.00K | Sale |
DERE WILLARD H |
Director | 46.44K | Stock Award(Grant) |
FRIBERG GREGORY R |
Officer | 51.82K | Sale |
GUYER CHARLES GREG |
Chief Technology Officer | 85.83K | Stock Award(Grant) |
HARDY ALEXANDER |
Chief Executive Officer | 218.89K | Stock Award(Grant) |
HOMBACH ROBERT J. CPA |
Director | 49.36K | Stock Award(Grant) |
HUBBARD CRISTIN |
Officer | 44.79K | Stock Award(Grant) |
MEIER RICHARD A |
Director | 126.93K | Stock Gift |
MUELLER BRIAN R |
Chief Financial Officer | 125.43K | Stock Award(Grant) |
Fundamentals
Market cap$10.88B
Enterprise value$14.21B
Revenue (TTM)$3.41B
Gross profit$1.74B
EBITDA$645.32M
Net income$72.97M
EPS (TTM)$0.37
Free cash flow$85.16M
Total cash$874.00M
Total debt$4.20B
Book value / share$32.66
Shares outstanding193.57M
Float192.63M
Short % of float5.22%
Dividend yield0.00%
Beta (5Y)0.22
Valuation & profitability ratios
Trailing P/E151.95
Forward P/E8.49
PEG ratio0.34
Price / sales—
Price / book1.72
EV / revenue4.17
EV / EBITDA22.02
Gross margin50.97%
Operating margin21.16%
Profit margin2.14%
Return on equity1.18%
Return on assets3.26%
Debt / equity66.47
Current ratio2.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $3.22B | $2.85B | $2.42B | $2.10B | +12.9% |
| Operating revenue | $3.22B | $2.85B | $2.42B | $2.10B | +12.9% |
| Cost of revenue | $717.44M | $580.24M | $532.06M | $503.02M | +23.6% |
| Gross profit | $2.50B | $2.27B | $1.89B | $1.59B | +10.1% |
| Research & development | $921.93M | $747.18M | $746.77M | $649.61M | +23.4% |
| Selling, general & admin | $1.15B | $1.01B | $892.40M | $823.20M | +14.3% |
| Total operating expense | $2.09B | $1.80B | $1.70B | $1.54B | +16.4% |
| Operating income | $409.50M | $474.24M | $185.78M | $57.41M | -13.7% |
| Net interest income | $64.00M | $62.22M | $41.00M | $3.63M | +2.9% |
| Pre-tax income | $482.48M | $541.76M | $188.56M | $149.58M | -10.9% |
| Tax provision | $133.58M | $114.90M | $20.92M | $8.02M | +16.3% |
| Net income | $348.90M | $426.86M | $167.65M | $141.56M | -18.3% |
| Net income to common | $348.90M | $426.86M | $167.65M | $141.56M | -18.3% |
| Basic EPS | 1.82 | 2.25 | 0.89 | 0.76 | -19.1% |
| Diluted EPS | 1.80 | 2.21 | 0.87 | 0.75 | -18.6% |
| EBIT | $493.38M | $554.43M | $205.90M | $163.39M | -11.0% |
| EBITDA | $572.94M | $650.86M | $310.28M | $265.36M | -12.0% |
| Basic shares | 191.79M | 190.03M | 187.83M | 185.27M | +0.9% |
| Diluted shares | 197.39M | 196.71M | 191.59M | 188.96M | +0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.31B | $942.84M | $755.13M | $724.53M | +39.1% |
| Cash & short-term investments | $1.56B | $1.14B | $1.07B | $1.29B | +37.2% |
| Accounts receivable | $908.21M | $660.53M | $633.70M | $461.32M | +37.5% |
| Inventory | $1.30B | $1.23B | $1.11B | $894.08M | +5.4% |
| Total current assets | $3.95B | $3.23B | $2.96B | $2.75B | +22.3% |
| Property, plant & equipment | $952.51M | $1.04B | $1.07B | $1.07B | -8.7% |
| Goodwill & intangibles | $410.04M | $451.48M | $490.90M | $534.77M | -9.2% |
| Total assets | $7.59B | $6.99B | $6.84B | $6.38B | +8.7% |
| Total current liabilities | $759.03M | $606.99M | $1.18B | $588.88M | +25.0% |
| Current debt | — | — | $493.88M | — | — |
| Long-term debt | $597.18M | $595.14M | $593.10M | $1.08B | +0.3% |
| Total debt | $605.86M | $602.71M | $1.10B | $1.09B | +0.5% |
| Total liabilities | $1.51B | $1.33B | $1.89B | $1.77B | +13.2% |
| Retained earnings | $154.21M | -$194.69M | -$621.55M | -$789.20M | +179.2% |
| Shareholder equity | $6.09B | $5.66B | $4.95B | $4.60B | +7.6% |
| Working capital | $3.19B | $2.63B | $1.78B | $2.16B | +21.7% |
| Net tangible assets | $5.68B | $5.21B | $4.46B | $4.07B | +9.0% |
| Shares issued | 192.30M | 190.76M | 188.60M | 186.25M | +0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $348.90M | $426.86M | $167.65M | $141.56M | — | -18.3% |
| Depreciation & amortisation | $79.56M | $96.43M | $104.39M | $101.97M | — | -17.5% |
| Stock-based compensation | $181.41M | $201.57M | $207.10M | $196.31M | — | -10.0% |
| Change in working capital | -$293.66M | -$216.40M | -$336.54M | -$96.38M | — | -35.7% |
| Operating cash flow | $827.99M | $572.84M | $159.26M | $175.90M | — | +44.5% |
| Capital expenditure | -$110.97M | -$97.42M | -$107.61M | -$131.54M | — | -13.9% |
| Investing cash flow | -$414.24M | $136.49M | -$111.24M | -$20.03M | — | -403.5% |
| Share buybacks | — | — | — | $0 | $0 | — |
| Financing cash flow | -$42.39M | -$526.45M | -$18.73M | -$18.65M | — | +91.9% |
| Free cash flow | $717.02M | $475.42M | $51.65M | $44.36M | — | +50.8% |
| End cash position | $1.31B | $942.84M | $755.13M | $724.53M | — | +39.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $989.71M | $766.21M | $874.57M | $776.13M | $825.41M | +29.2% |
| Operating revenue | $989.71M | $766.21M | $874.57M | $776.13M | $825.41M | +29.2% |
| Cost of revenue | $202.79M | $195.00M | $275.71M | $140.09M | $150.09M | +4.0% |
| Gross profit | $786.91M | $571.21M | $598.86M | $636.05M | $675.32M | +37.8% |
| Research & development | $206.95M | $178.80M | $192.41M | $409.48M | $161.31M | +15.7% |
| Selling, general & admin | $395.50M | $258.30M | $446.20M | $268.40M | $232.30M | +53.1% |
| Total operating expense | $675.94M | $441.58M | $643.46M | $682.73M | $398.45M | +53.1% |
| Operating income | $110.97M | $129.63M | -$44.60M | -$46.68M | $276.87M | -14.4% |
| Net interest income | -$52.81M | $7.60M | $16.43M | $15.28M | $16.15M | -794.8% |
| Pre-tax income | $61.38M | $141.20M | -$27.15M | -$26.32M | $297.87M | -56.5% |
| Tax provision | $16.62M | $35.68M | $19.42M | $4.42M | $57.34M | -53.4% |
| Net income | $44.76M | $105.53M | -$46.57M | -$30.74M | $240.53M | -57.6% |
| Net income to common | $44.76M | $105.53M | -$46.57M | -$30.74M | $240.53M | -57.6% |
| Basic EPS | 0.23 | 0.55 | -0.24 | -0.16 | 1.25 | -58.2% |
| Diluted EPS | 0.23 | 0.54 | -0.24 | -0.16 | 1.23 | -57.4% |
| EBIT | $124.68M | $156.16M | -$24.38M | -$23.75M | $300.55M | -20.2% |
| EBITDA | $222.32M | $172.57M | -$3.94M | -$5.26M | $319.11M | +28.8% |
| Basic shares | 193.42M | 192.50M | 192.22M | 192.03M | 191.91M | +0.5% |
| Diluted shares | 194.47M | 197.67M | 192.22M | 192.03M | 197.09M | -1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $874.00M | $2.22B | $1.31B | $1.25B | $1.21B | -60.7% |
| Cash & short-term investments | $874.00M | $2.22B | $1.56B | $1.48B | $1.43B | -60.7% |
| Accounts receivable | $1.06B | $903.91M | $908.21M | $790.27M | $855.86M | +17.4% |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | +40.0% |
| Total current assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | -13.8% |
| Property, plant & equipment | $989.99M | $958.07M | $952.51M | $1.04B | $1.03B | +3.3% |
| Goodwill & intangibles | $5.54B | $400.86M | $410.04M | $429.31M | $435.82M | +1,280.8% |
| Total assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | +36.5% |
| Total current liabilities | $1.66B | $793.15M | $759.03M | $798.44M | $684.25M | +109.8% |
| Current debt | $658.20M | — | — | — | — | — |
| Long-term debt | $3.53B | $1.43B | $597.18M | $596.66M | $596.16M | +146.7% |
| Total debt | $4.20B | $1.44B | $605.86M | $604.24M | $603.87M | +191.9% |
| Total liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | +127.1% |
| Retained earnings | $304.50M | $259.73M | $154.21M | $200.78M | $231.52M | +17.2% |
| Shareholder equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | +1.8% |
| Working capital | $2.31B | $3.81B | $3.19B | $3.06B | $3.12B | -39.5% |
| Net tangible assets | $786.58M | $5.81B | $5.68B | $5.63B | $5.59B | -86.5% |
| Shares issued | 193.54M | 193.27M | 192.30M | 192.10M | 192.00M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $44.76M | $105.53M | -$46.57M | -$30.74M | $240.53M | -57.6% |
| Depreciation & amortisation | $97.64M | $16.41M | $20.44M | $18.49M | $18.56M | +495.0% |
| Stock-based compensation | $75.69M | $43.46M | $46.91M | $49.27M | $47.53M | +74.2% |
| Change in working capital | -$54.39M | $39.07M | -$164.05M | $118.93M | -$158.07M | -239.2% |
| Operating cash flow | $168.11M | $220.65M | $99.64M | $368.69M | $185.27M | -23.8% |
| Capital expenditure | -$34.25M | -$20.92M | -$43.09M | -$33.75M | -$17.37M | -63.7% |
| Investing cash flow | -$5.10B | $725.53M | -$42.45M | -$330.96M | -$12.59M | -803.2% |
| Financing cash flow | $2.74B | $813.17M | $3.16M | -$2.17M | -$4.60M | +236.8% |
| Free cash flow | $133.86M | $199.73M | $56.55M | $334.94M | $167.90M | -33.0% |
| End cash position | $874.00M | $3.07B | $1.31B | $1.25B | $1.21B | -71.6% |
Options analytics
Put / call volume
0.12
Call-heavy session
Put / call open interest
0.49
Positioning, not flow
Max pain
60.00
+6.7% from spot
ATM implied vol
55.4%
Nearest strike to spot
Skew (10% OTM)
+12.9%
Puts bid over calls
Call volume
760
Contracts, this expiry
Put volume
93
Contracts, this expiry
Heaviest call OI
62.50
1.40K contracts
Heaviest put OI
60.00
904 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.95 | 1.20 | +25.8% |
| Mar 2026 | 0.91 | 0.76 | -16.9% |
| Dec 2025 | 0.56 | 0.46 | -17.9% |
| Sep 2025 | 0.34 | 0.12 | -64.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.25 | 14 | $1.03B | +32.2% |
| Next quarter | 1.75 | 15 | $1.12B | +28.5% |
| Current year | 4.94 | 18 | $3.91B | +21.3% |
| Next year | 6.62 | 18 | $4.47B | +14.4% |
Analyst targets & ownership
Mean target$91.62
High target$124.00
Low target$60.00
Implied upside63.86%
Analyst count26
ConsensusBUY
Strong buy / Buy6 / 14
Hold7
Sell / Strong sell0 / 0
Held by insiders0.34%
Held by institutions103.53%
Institutions holding757
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
59.25
-5.64% from price
SMA 20
62.01
-9.34% from price
SMA 50
63.87
-11.97% from price
SMA 100
60.18
-7.09% from price
SMA 200
58.72
-4.26% from price
EMA 12
59.63
-6.24% from price
EMA 26
61.62
-9.27% from price
EMA 50
62.12
-9.99% from price
RSI (14)
25.8
Oversold
MACD (12,26,9)
-1.99
Hist -0.69
ATR (14)
1.53
2.73% of price
Realised vol 30D
23.2%
Annualised
Bollinger upper
68.20
20, 2σ
Bollinger lower
55.82
20, 2σ
50 / 200 cross
Golden
63.87 vs 58.72
Trend bias
Below 200
-4.26%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.39
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
23.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-22.5%
Peak to trough
Max drawdown 5Y
-57.6%
Peak to trough
ATR 14
1.53
2.73% of price
Beta (reported)
0.22
5Y monthly, from filing
Short interest
Shares short
10.08M
Prior 10.20M
Change vs prior
-1.2%
Shorts covering
% of float
5.22%
Normal
% of shares out
5.21%
Against total outstanding
Days to cover
5.6
Crowded exit
Float
192.63M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Sep 1, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 31, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Aug 31, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Aug 19, 26 | BMO Capital | INITIATED | Outperform | Outperform |
| Aug 18, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Aug 17, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 17, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 10, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Aug 7, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-30
Corporate Changes & Voting Matters
8-K · 2026-09-15
Corporate Changes & Voting Matters
8-K · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-09-01
Corporate Changes & Voting Matters
8-K · 2026-08-31
Corporate Changes & Voting Matters
8-K · 2026-08-18
Offering Registrations
S-8 · 2026-08-06
Corporate Changes & Voting Matters
8-K/A · 2026-07-13
Headlines
BioMarin Expects Pre-tax Charges Related to Alesta Acquisition to Impact Q3 Adjusted EPS
MT Newswires · 6h ago
BioMarin Appoints Cara Bauer as Chief People Officer
PR Newswire · 1d ago
BioMarin Says 5-Year Data Shows Durable Efficacy of Pombiliti Plus Opfolda in Pompe Disease
MT Newswires · 5d ago
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
PR Newswire · 5d ago
The Strategic Financial Case for BioMarin Pharmaceutical (BMRN)
Insider Monkey · 6d ago
BioMarin and Profluent partner on AI-designed enzyme therapies
Pharmaceutical Technology · 6d ago
BioMarin and Profluent partner on AI-designed enzyme therapies
Hospital Management · 6d ago
Profluent Partners With BioMarin to Design Novel Medicines Using AI
Business Wire · 7d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.